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W orldwide, an estimated 37 million people are livingwith HIV infection, and more than 2 million newinfections are diagnosed annually.1 HIV-positive
individuals are at increased risk for both acute and chronic
kidney disease (CKD). The classic kidney disease of HIV
infection, HIV-associated nephropathy (HIVAN), has become
less common with widespread use of antiretroviral therapy
(ART); however, there has been a simultaneous increase in the
prevalence of other kidney diseases. HIV-positive individuals
are also exposed to lifelong ART, with the potential to cause
or exacerbate kidney injury. Newer guidelines recommending
earlier initiation of ART may further reduce the incidence of
HIVAN, but the overall risk-beneﬁt for kidney health is
unknown.
Clinical guidelines for CKD prevention and treatment in
HIV-positive individuals are extrapolated from studies in the
general population,2 and current therapies do not target
unique HIV-related pathways and genetic factors that
contribute to CKD progression. In March 2017, Kidney
Disease: Improving Global Outcomes (KDIGO) convened a
multidisciplinary, international panel of clinical and scientiﬁc
experts to identify and discuss key issues relevant to the
optimal diagnosis and management of kidney disease in HIV-
positive individuals. The primary goals were to deﬁne the
pathology of kidney disease in the setting of HIV infection;
describe the role of genetics in the natural history, diagnosis,
and treatment of kidney disease in HIV-positive individuals;545
Table 1 | Pathologic classiﬁcation of HIV-related kidney
diseases
I. Glomerular-dominanta
a. Podocytopathies (all characterized by extensive foot process
effacement)b
i. Classic HIVAN
ii. FSGS (NOS) in the setting of HIV
iii. Minimal change disease in the setting of HIV
iv. Diffuse mesangial hypercellularity in the setting of HIV
v. Other podocytopathy in the setting of HIV
b. Immune complex-mediated glomerular diseasea
i. IgA nephropathy in the setting of HIV
ii. Lupus-like glomerulonephritis in the setting of HIV
iii. Lupus nephritis in the setting of HIV
iv. Membranous nephropathy in the setting of HIV
 Indicate whether HBV positive, HCV positive, PLA2R positive
(should not preclude workup for other secondary causes)
v. Membranoproliferative pattern glomerulonephritis in the setting of
HIV
 Indicate whether HCV positive (should not preclude workup for
other secondary causes)
vi. Endocapillary proliferative and exudative glomerulonephritis in the
setting of HIV
 Post-streptococcal, staphylococcal-associated, other
vii. Fibrillary or immunotactoid glomerulonephritis in the setting of HIV
viii. Other immune complex disease in the setting of HIV
II. Tubulointerstitial-dominanta
a. Tubulointerstitial injury in the setting of classic HIVAN
i. Hyaline droplet tubulopathy
ii. Tubular microcysts
iii. Tubulointerstitial inﬂammation
b. Acute tubular injury or acute tubular necrosis
i. Ischemic
ii. Toxic (associated with ART vs. other)
c. Drug-induced tubulointerstitial nephritis (other than ART)
i. Antibiotics
ii. Proton pump inhibitors
iii. NSAIDs
iv. Other
d. Direct renal parenchymal infection by pathogens (bacterial, viral,
fungal, protozoal, etc.)
e. Immunologic dysfunction-related tubulointerstitial inﬂammation
i. Diffuse inﬁltrative lymphocytosis syndrome (DILS)
ii. Immune reconstitution inﬂammatory syndrome (IRIS)
f. Other tubulointerstitial inﬂammation in the setting of HIV
III. Vascular-dominanta
a. Thrombotic microangiopathy in the setting of HIV
b. Arteriosclerosis
IV. Other, in the setting of HIV infection
a. Diabetic nephropathy
b. Age-related nephrosclerosis
ART, antiretroviral therapy; HBV, hepatitis B virus; HCV, hepatitis C virus; FSGS, focal
segmental glomerulosclerosis; HIVAN, HIV-associated nephropathy; NOS, not
otherwise speciﬁed; NSAID, nonsteroidal anti-inﬂammatory drug; PLA2R, M-type
phospholipase A2 receptor.
aIndicates likelihood of HIV causality.
bIndicates association with APOL1 risk allele genotype.
KDIGO execu t i ve conc lu s i ons CR Swanepoel et al.: Kidney disease and HIV: a KDIGO conference reportcharacterize the renal risk-beneﬁt of ART; and deﬁne best
practices to delay the progression of kidney disease and to
treat end-stage kidney disease (ESKD) in HIV-positive
individuals.
Renal pathology in the setting of HIV infection
The spectrum of renal pathology in HIV-positive individuals
is diverse, including lesions directly related to intrarenal
HIV gene expression and lesions related to comorbidities,
drug effects, immune dysregulation, and co-infections.3
Kidney biopsy is required to distinguish between these le-
sions. A useful approach to classiﬁcation is based on the
major tissue compartment affected (Table 1). A brief
description of each histologic lesion is provided below, and
more comprehensive descriptions are available in the Sup-
plementary Appendix.
Glomerular-dominant diseases: podocytopathy. Glo-
merular-dominant diseases include 2 main subcategories:
podocytopathies and immune complex–mediated.
Four major subtypes of podocytopathy are seen in the
setting of HIV: classic HIVAN, focal segmental glomerulo-
sclerosis (FSGS) not otherwise speciﬁed (NOS), and rarer
cases of minimal change disease and diffuse mesangial
hypercellularity.4 All exhibit extensive podocyte foot process
effacement and proteinuria, with absent or minimal im-
mune complex deposition. There is a well-established
causal relationship between HIVAN and HIV infection,
mediated by direct HIV infection of renal epithelial cells,
intrarenal viral gene expression, and dysregulation of host
genes governing cell differentiation and cell cycle.5 The role
of genetic susceptibility in the pathogenesis of HIVAN and
other podocytopathies is discussed in detail in the next
section.
We recommend distinguishing classic HIVAN from FSGS
(NOS) in the setting of HIV infection. Direct causality of HIV
can only be established with reasonable certainty in classic
HIVAN and congenital cases of podocytopathy in infants born
to HIV-positive mothers. We recommend that the biopsy
report should indicate the degree of certainty that the
pathology is causally related to HIV infection as high,
moderate, or low.
Classic HIVAN. Classic HIVAN is deﬁned as collapsing
glomerulopathy and attendant tubulointerstitial disease,
including tubular microcyst formation, interstitial inﬂam-
mation, and tubular injury (Figure 1).6,7 Glomerular
“collapse” is deﬁned as at least 1 glomerulus with collapse of
glomerular basement membranes accompanied by hypertro-
phy and hyperplasia of the overlying glomerular epithelial
cells. These hyperplastic cells may ﬁll the urinary space,
forming pseudocrescents.8,9
By electron microscopy, diffuse podocyte foot process
effacement and endothelial tubuloreticular inclusions
(interferon footprints) are classic features.6,7 By immuno-
ﬂuorescence, there may be staining for IgM, C3, and C1q in
collapsed segments and mesangial areas.7 Protein resorption546droplets may stain for albumin and Ig. In late stages, the
sclerotic tuft is retracted into a tight solid sphere, capped
by a monolayer of cobblestone epithelium; this has been
described as resembling a “fetal glomerulus.”10 Phenotypic
studies suggest that the glomerular epithelial cell monolayer
is composed of parietal epithelial cells.8 In some
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Figure 1 | Classic HIV-associated nephropathy (HIVAN) and focal segmental glomerulosclerosis (FSGS) not otherwise speciﬁed (NOS) in
the setting of HIV. (a,b) Classic HIVAN shows typical global collapse of the glomerular tuft with loss of luminal patency and hypertrophy
and hyperplasia of the overlying glomerular epithelial cells, some of which contain intracytoplasmic protein resorption droplets (a, Jones
methenamine silver x400; b, Masson trichrome, x400). (c) The tubulointerstitium shows focal tubular microcysts (arrow) containing glassy casts,
associated with tubular atrophy, interstitial ﬁbrosis, and inﬂammation (Masson trichrome, x200). (d) There is marked foot process effacement
overlying the collapsed capillaries associated with glomerular epithelial cell hyperplasia forming a pseudocrescent. Some glomerular epithelial
cells contain numerous intracytoplasmic protein resorption droplets. No immune-type electron dense deposits are seen (electron micrograph
x4000). (e) Glomerular endothelial cells may contain intracytoplasmic tubuloreticular inclusions (arrows). Foot processes are effaced (electron
micrograph, x40,000). (f) FSGS (NOS) in the setting of HIV shows discrete segmental scars with segmental adhesions to Bowman’s capsule.
No collapsing features or glomerular epithelial cell hyperplasia are identiﬁed (H&E, x400). To optimize viewing of this image, please see the
online version of this article at www.kidney-international.org.
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(NOS).7
Tubulointerstitial disease is an invariable component of
HIVAN and often appears out of proportion to the glomer-
ular disease,6,7 causing kidney enlargement and hyperechoic
appearance by ultrasound. Tubular microcysts are dilated
tubules (at least 3-fold larger than normal) containing glassy
proteinaceous casts and lined by simpliﬁed epithelium.
Tubular microcysts are easily distinguished from tubular
thyroidization based on their larger diameter, irregular size,
and the absence of tubular atrophy or colloid-type casts.11
The microcysts may involve all tubular segments, and
intracellular viral transcript expression has been demon-
strated.12 Prominent interstitial inﬂammation7 and tubular
degenerative and regenerative changes may also occur.13
Interstitial edema in the acute phase is followed by ﬁbrosis
and tubular atrophy.
FSGS (NOS) in the setting of HIV. In ART-treated patients,
noncollapsing FSGS (NOS) is more commonly encountered
at biopsy.9,14–16 Causality is presumed when no other etiology
for FSGS can be identiﬁed. Viral load is often undetectable,Kidney International (2018) 93, 545–559and biopsy ﬁndings may be difﬁcult to distinguish from
arterionephrosclerosis of hypertension, aging, and APOL1-
associated nephropathy. Such cases typically lack prominent
tubulointerstitial disease, and the degree of podocyte efface-
ment is generally less severe than in HIVAN (Figure 1). These
differences have been hypothesized to reﬂect attenuation of
the renal phenotype by ART.9
Podocytopathy in perinatal HIV infection. In addition to
classic HIVAN, children with perinatal HIV infection can
present with minimal change disease or diffuse mesangial
hypercellularity with numerous endothelial tubuloreticular
inclusions and marked foot process effacement.17 Tubular
microcysts and interstitial inﬂammation are often lacking.
Such cases are rare in the ART era.
Glomerular-dominant diseases: immune complex kidney
disease in the setting of HIV. Numerous forms of immune
complex-mediated glomerular disease have been reported in
HIV-positive individuals.18 We recommend that the
commonly used term “HIV immune complex kidney disease”
(HIVICK) be replaced with a speciﬁc description of the
pattern of immune complex disease “in the setting of HIV.”547
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of disease and the lack of certainty of HIV causality in most
cases. Early studies that eluted glomerular immune deposits
and demonstrated immune complexes containing HIVantigen
and speciﬁc anti-HIV antibody were performed on a small
number of well-characterized cases in the research setting and
are not practicable in routine pathology laboratories.19,20 Re-
ﬂex diagnosis as HIVICK may preclude workup for other
secondary, treatable causes.
A unique lupus-like nephritis with full-house immune
staining but negative serologies and no clinical signs of sys-
temic lupus erythematosus has been reported in HIV-positive
individuals;21 true lupus nephritis also occurs.22 It remains
unclear whether IgA nephropathy in the setting of HIV is
coincidental and related to undergalactosylated IgA1 or due to
deposition of IgA directed to viral antigen, as demonstrated
in a well-characterized case.19 An unusual ultrastructural
appearance of subepithelial deposits, or “ball in cup” lesion,
has been described in reports from South Africa,10,23 but is
rarely observed in other settings. Other secondary causes
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and membranoproliferative glomerulonephritis (hepatitis C
virus co-infection).24–26
Tubulointerstitial disease in the setting of HIV. As described
above, classic HIVAN is a pan-nephropathy with an impor-
tant tubulointerstitial component;6,7 in biopsies with under-
sampled glomeruli, the characteristic glomerular lesions may
not be demonstrable. Acute tubular necrosis may occur in
association with sepsis, volume depletion, and other ischemic
or toxic insults.4 The commonly used antiretroviral agent
tenofovir disoproxil fumarate can cause proximal tubulopathy
with characteristic dysmorphic mitochrondria (Figure 2).27
Tubulointerstitial nephritis can occur secondary to
antibiotics, proton pump inhibitors, nonsteroidal anti-
inﬂammatory drugs, protease inhibitors, and other medica-
tions, as well as in response to mycobacterial infection.28–30
Direct infection of the renal parenchyma by other patho-
gens can also occur.7
Two rare but distinct forms of tubulointerstitial injury
relate to immunologic dysfunction in the setting of HIV
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Table 2 | Prevalence of APOL1 high-risk genotypes and asso-
ciation with kidney disease in HIV-positive African Americans








13% 72% 29 (14, 68) 49
HIVAN African American
(n ¼ 60)
13% 62% – 54
HIVAN South Africa
(n ¼ 38)
3% 79% 89 (18, 912) 51
HIVþ FSGS African American
(n ¼ 35)
13% 63% – 57
HIVþ FSGS South Africa
(n ¼ 22)
3% 8% 2.1 (0.03, 44) 51
HIVþ ICD African American
(n ¼ 31)
13% 3% – 57
HIVþ ICD South Africa
(n ¼ 12)
3% 25% 5.6 (0.4, 86) 51
APOL1, apolipoprotein L1; CI, conﬁdence interval; FSGS, focal segmental glomer-
ulosclerosis; HIVAN, HIV-associated nephropathy; ICD, immune complex kidney
disease.
Table 3 | Features of APOL1-mediated kidney disease in the
setting of HIV
 MYH9 variants are not independently associated with HIVAN or FSGS
(NOS)45,52,152
 APOL1 kidney disease manifests as HIVAN or FSGS (NOS) with or
without microcystic tubular dilatation49,56,57
 S342G and N388Y389/– confer risk of kidney disease; therefore geno-
typing only the APOL1 G1 rs73885319 missense and G2 rs71785313
indel (i.e., insertion-deletion mutations) variants are sufﬁcient to
determine risk of CKD49
 HIVAN is associated with low CD4þ cell counts, and often improves
with effective ART56
 HIV-associated FSGS is associated with higher CD4þ cell counts and
occurs in patients undergoing ART56
 APOL1 high-risk genotypes are associated with progression to ESKD in
HIV-positive patients with non-HIVAN kidney diseases57
 Histological features of HIVAN in patients carrying 2 copies of APOL1
risk variants are similar to those carrying 0 or 1 copy54
 HIV-positive children with CKD and high-risk genotypes have lower
eGFR and experience more rapid progression58,153
 Multiple mechanisms have been proposed for APOL1-mediated podo-
cyte injury, but they converge in perturbations of endosomal trafﬁcking,
increased membrane permeability, and cytotoxicity61,63–65
 APOL1, a component of the innate immune system, is up-regulated by
interferons61,62
 High levels of APOL1 may be a “second hit” and sufﬁcient to cause
kidney disease61,62
APOL1, apolipoprotein L1; ART, antiretroviral therapy; CKD, chronic kidney disease;
eGFR, estimated glomerular ﬁltration rate; ESKD, end-stage kidney disease; FSGS
(NOS), focal segmental glomerulosclerosis, not otherwise speciﬁed; HIVAN,
HIV-associated nephropathy; MYH9, myosin heavy chain 9 gene.
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in approximately 10% of cases.31–33 Immune reconstitution
inﬂammatory syndrome is an inﬂammatory disorder associ-
ated with paradoxical unmasking or worsening of preexisting
infectious processes after ART initiation,34 rarely involving
the kidney. Both conditions are characterized by prominent
CD8 T-cell inﬁltrates.
Vascular-dominant diseases in the setting of HIV.
Thrombotic microangiopathy was reported in the early years
of the AIDS epidemic, but is rare in the ART era.35 A role for
direct endothelial dysregulation by HIV has been proposed.36
Other pathologies in the setting of HIV. As patients with
HIV infection age, comorbid kidney diseases such as diabetic
nephropathy and arterionephrosclerosis are increasingly
common. When secondary FSGS develops in these contexts,
the potential overlap with HIV-related podocytopathy can be
diagnostically challenging. Molecular approaches demon-
strating renal epithelial cell infection by HIV have been used
in the research setting for decades, but have not been incor-
porated into routine diagnostic practice.37 In addition to
these established approaches, several novel and emerging
techniques could be incorporated into research and diag-
nostic renal pathology to better characterize the causal rela-
tionship between HIV and speciﬁc histologic lesions and to
further delineate the host pathways involved. The conference
attendees identiﬁed several particularly relevant techniques
(Supplementary Table S1).38,39
Genetics/genomics of kidney disease in the setting of HIV
infection
Classic HIVAN occurs predominantly in individuals of
African ancestry, with 18- to 50-fold increased prevalence.40
Two studies involving mapping by admixture linkage
disequilibrium published in 2008 identiﬁed a region on
chromosome 22 strongly associated with idiopathic FSGS
and HIVAN in African Americans;41,42 however, ﬁne-
mapping revealed no coding variants to explain the associ-
ation of intronic single-nucleotide polymorphisms in the
candidate gene MYH9 with kidney disease.43,44 Subsequently,
using data from the 1000 Genomes Project, Genovese et al.
identiﬁed 2 missense variants (G1 allele) and a 6 bp deletion
(G2 allele) in the adjacent APOL1 gene that were recessively
associated with FSGS and nondiabetic ESKD.45 APOL1 en-
codes apolipoprotein L1, which confers innate immunity
against most strains of Trypanosoma brucei;46,47 G2 variants
extend immunity to T.b. rhodesiense and G1 associates with
asymptomatic carriage of T.b. gambiense, the causes of acute
and chronic African human trypanosomiasis, respec-
tively.45,48 Coding variants in APOL1 are present only on
African-ancestry haplotypes.49,50
APOL1 was strongly associated with FSGS (odds ratio
[OR] 17) and HIVAN (OR 29) in African Americans and with
HIVAN in South Africans (OR 89).49,51 In contrast, HIV-
positive Ethiopians, who lack APOL1 risk variants, do not
develop HIVAN.52 Subsequent studies have conﬁrmed the
strong association between the high-risk genotypes and theKidney International (2018) 93, 545–559diagnosis of HIVAN (Table 2). The estimated lifetime risk
associated with carrying 2 APOL1 risk alleles is 4% for FSGS
in the absence of HIV infection, and as high as 50% for
HIVAN (Supplementary Table S2).53 Despite the strong as-
sociation, w20% to 30% of African Americans with HIVAN
have 0 or 1 APOL1 risk allele, suggesting that other genetic,
viral, or environmental factors contribute to HIVAN.54549
KDIGO execu t i ve conc lu s i ons CR Swanepoel et al.: Kidney disease and HIV: a KDIGO conference reportCharacteristics of APOL1-mediated kidney disease are sum-
marized in Table 3.
The distribution of the APOL1 coding variants varies
greatly among sub-Saharan African populations, with the
highest frequencies reported in Western Africa (>40% for
G1) and much lower frequencies elsewhere in Africa
(Supplementary Figure S1).50,52,55 As a consequence of the
West African diaspora in the Americas and more recent
African emigrations, APOL1 variants are widely dispersed
globally (e.g., 21% and 13% for G1 and G2, respectively, in
African Americans).45,50
Prediction of histology. Given the strong genetic associa-
tion, investigators in the United States (US) evaluated whether
APOL1 genotype could be used to predict HIVAN or FSGS
(NOS) histology in HIV-positive patients of African
descent.56 Inclusion of the high-risk genotype did not
signiﬁcantly add to a predictive model including CD4þ cell
count and HIV-RNA, suggesting that APOL1 genotype cannot
replace kidney biopsy for deﬁnitive diagnosis of HIVAN.
Carriage of APOL1 high-risk genotypes in HIV-positive
individuals is not associated with immune complex kidney
disease (Table 2). In a US series, high-risk genotypes were
present in only 3% of patients with biopsy-proven immune
complex disease.57 Similarly, in a South African series, high-
risk genotypes were present in 79% of HIVAN cases but in
only 25% of those with HIV and immune complex kidney
disease.51
Renal survival and ESKD risk. In general population
studies, the high-risk APOL1 genotypes have been associated
with increased risk of CKD progression and with lower esti-
mated glomerular ﬁltration rate (eGFR).58 In children with
perinatal HIV infection, those with a high-risk genotype had
3-fold increased odds of CKD and presented at a younger
median age compared with those with 0 or 1 risk allele.51 In
HIV-positive adults with non-HIVAN kidney disease on
biopsy, carriage of 2 APOL1 risk alleles was associated with
more rapid progression and a 2-fold greater risk of ESKD.57
Carriage of 2 APOL1 risk alleles has been associated with
proteinuria in HIV-infected women and with accelerated
decline in longitudinal kidney function in unsuppressed HIV-
infected men.59,60
Mechanisms of APOL1-mediated disease. Two APOL1 risk
alleles are required to confer increased risk of kidney disease.
However, the presence of high-risk genotypes in healthy
populations suggests that disease expression requires a “sec-
ond hit,” such as infections (e.g., HIV or viral hepatitis),
interferon, gene-gene interactions, illicit drug use, and other
CKD risk factors.
The mechanism of APOL1-mediated kidney disease is
currently unknown. Evidence from in vitro experiments in
human cells and APOL1 transgenic mouse models suggests
that interferon upregulates APOL1 expression, causing
podocyte injury.61,62 Intracellular apolipoprotein L1 in renal
epithelium may cause apoptosis or autophagy by increasing
cellular and mitochondrial membrane permeability.63–65 In
cell culture, G1 and G2 APOL1 variants induce intracellular550loss of potassium, cell swelling, and cell lysis.66 Studies in
yeast, Drosophila, and human cells indicate that variant
apolipoprotein L1 depolarizes cell membranes, which dis-
rupts intracellular processes including endosomal trafﬁcking,
vesicle acidiﬁcation, and mitochondrial function.63–65
In vivo, the expression of high-risk APOL1 variants
in transgenic mouse models has produced variable effects.
In a model with inducible APOL1 expression, high-risk
variants disrupted endosomal trafﬁcking and vesicle acidiﬁ-
cation, similar to the effects observed in vitro. Affected
animals developed podocyte death, proteinuria, and glomer-
ulosclerosis.61 However, another transgenic mouse model
with constitutive expression of APOL1-G2 did not develop
kidney disease.67
APOL1 is encoded in the genome of only a few primate
species, complicating the extrapolation of data from murine
models. Mechanistic studies have also been limited by the use
of overexpression assays. In vitro, the overexpression of wild-
type APOL1-G0 in cultured human renal epithelial cells also
induces cell death, suggesting that the overexpression model
may not be biologically relevant.62,68,69
Antiretroviral therapy (ART) nephrotoxicity
HIV treatment guidelines recommend immediate initiation of
ART in all HIV-positive individuals. Immuno-virological
control is an important strategy to reduce the incidence
of acute kidney injury (AKI) and HIV-related kidney
diseases.70–73
The presence of CKD affects the choice and dosing of
renally cleared antiretrovirals. Kidney function and CKD risk
factors should be assessed prior to ART initiation (Figure 3).
CKD risk scores have been developed to guide clinicians,
although future studies are needed to determine their utility
in diverse populations (Supplementary Table S3).74,75
The widely used antiretroviral agent tenofovir disoproxil
fumarate (TDF) is generally safe and well tolerated, but has
important potential for cumulative nephrotoxicity. Sub-
clinical proximal tubular dysfunction (low-level proteinuria
and excessive phosphaturia) is common, and approximately
1% to 2% of recipients develop treatment-limiting tubul-
opathy.76 Risk factors for tubulopathy include aging, im-
munodeﬁciency, diabetes, prolonged exposure, and
concomitant use of didanosine or ritonavir-boosted protease
inhibitors.77 Severe tubulopathy may progress to eGFR
decline, osteomalacia, and pathological fractures. In large
observational studies, TDF has also been associated with
decreased eGFR or creatinine clearance,78,79 as well as with
rapid eGFR decline and proteinuria.78,79 Co-administration
of TDF with ritonavir-boosted protease inhibitors increases
the risk.78,79 Although not well studied, the newer phar-
macoenhancer cobicistat also increases tenofovir exposure
and may increase the risk of toxicity. TDF discontinuation
and switches from TDF to the newer prodrug tenofovir
alafenamide (TAF) have been associated with improved
kidney function, although the long-term safety of TAF is not
known.80–83Kidney International (2018) 93, 545–559








HepaƟƟs C co-infecƟon 
Immunodeficiency    
Diabetes mellitus 
Uncontrolled hypertension  
Avoid nephrotoxic ART* 
(TDF, IDV, ATV, LPV)
Standard ART   
(local guidelines)
Age <50
History of cardiovascular disease
Figure 3 | Recommendations at starting ART. *If suitable alternatives available. ART, antiretroviral therapy; ATV, atazanavir; CKD, chronic
kidney disease; eGFR, estimated glomerular ﬁltration rate (CKD-EPI, expressed in ml/min per 1.73 m2); IDV, indinavir; LPV, lopinavir; TDF,
tenofovir disoproxil fumarate; uPCR, urine protein-to-creatinine ratio (values above are in mg/g; multiply by 0.10 to obtain values in mg/mmol).
CR Swanepoel et al.: Kidney disease and HIV: a KDIGO conference report KD IGO execu t i ve conc lu s i onsAny drug (antiretroviral or other) may cause interstitial
nephritis. New-onset eGFR decline or proteinuria should
prompt careful review of CKD risk factors and medica-
tions.29,84 Among antiretrovirals, atazanavir and indinavir
have been most commonly linked to interstitial nephritis and
nephrolithiasis; other protease inhibitors have been impli-
cated in case reports.85–89
Observational cohort studies have also linked atazanavir
and lopinavir/ritonavir to rapid eGFR decline and incident
CKD,78,79 and switching from ritonavir-boosted atazanavir or
lopinavir to boosted darunavir has been associated with
improved kidney function.90 In settings where TAF, abacavir,
and darunavir are available, the use of TDF, atazanavir, and
lopinavir/ritonavir should ideally be avoided in those with
CKD, rapid eGFR decline (>3–5 ml/min per 1.73 m2 per
year), or at high CKD risk. The threshold for avoiding or
discontinuing these agents may be inﬂuenced by local
circumstances. In resource-limited settings, TDF dose adap-
tation may be an option. Dual therapy (i.e., boosted protease
inhibitor plus lamivudine or raltegravir) has been proposed as
a way to avoid concomitant use of boosted protease inhibitors
with TDF, thereby minimizing the nephrotoxic potential.91–93
Pharmacological considerations. Several antiretrovirals
require dose adjustment in individuals with decreased eGFR
(Supplementary Table S4). If continued use of TDF is
required when eGFR is <60 ml/min per 1.73 m2 (or <70 ml/
min per 1.73 m2 with eGFR decline), dose adjustment should
be considered.Kidney International (2018) 93, 545–559Drug-drug interactions are common with ART. Several
antiretrovirals induce or inhibit absorption (through P-
glycoprotein), hepatic metabolism (through the cytochrome
P450 system or glucuronidation), and/or tubular excretion
(through organic anion and cation transporters, and multi-
drug resistant or multidrug and toxin extrusion proteins) of
co-administered medications. We recommend that clinicians
consult available resources such as www.hiv-druginteractions.
org.
CKD progression and ESKD in the setting of HIV infection
Risk factors for CKD. Both HIV-related and traditional
CKD risk factors inﬂuence CKD development and progression
(Figure 4). With improved longevity among HIV-positive in-
dividuals, traditional CKD risk factors, particularly
hypertension and diabetes, are of increasing concern world-
wide.94–96Hepatitis B virus (HBV) and hepatitis C virus (HCV)
co-infections are associated with a 2- to 3-fold increased risk of
progressive CKD.97,98 Other co-infections such as tuberculosis
and syphilis may also contribute to CKD risk.99–101 In addition,
severe AKI has been associated with a 3.8- to 20-fold increased
risk of progression to ESKD.102
CKD screening and monitoring. Studies to inform the
optimal CKD screening and monitoring strategies among
HIV-positive individuals are lacking. Until such studies exist,
current CKD guidelines should be followed.2,103 CKD
screening is recommended at the time of HIV diagnosis and
ART initiation or modiﬁcation (Figure 5).551
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Figure 4 | Risk factors and underlying etiologies of CKD in HIV-positive individuals. APOL1, apolipoprotein L1; ABCC, ATP-binding cassette
transporter proteins; ART, antiretrovial therapy; CKD, chronic kidney disease; FSGS (NOS), focal segmental glomerulosclerosis, not otherwise
speciﬁed; GN, glomerulonephritis; HIVAN, HIV-associated nephropathy.
KDIGO execu t i ve conc lu s i ons CR Swanepoel et al.: Kidney disease and HIV: a KDIGO conference reportSerum creatinine is the preferred biomarker for esti-
mating GFR.2,103 Serum cystatin C may be considered in
patients receiving medications that alter tubular creatinine
handling. Cystatin C may also better predict long-term
mortality,104,105 but is susceptible to bias in the setting of
inﬂammation. The serum creatinine-based CKD-EPI equa-
tion is generally preferred;2,103 however, none of the avail-
able estimates have been validated in diverse populations or
in the setting of drugs that alter creatinine secretion.106–108
Use of the antiretrovirals dolutegravir or rilpivirine or the
pharmacoenhancers ritonavir or cobicistat may result in
average reductions in calculated creatinine clearance of
around 5 to 20 ml/min, which should be taken into account
when interpreting eGFR or creatinine clearance.109 Clini-
cians should also be aware that serum creatinine measure-
ments may not be standardized in resource-limited regions
and that extrarenal factors may alter both serum creatinine
and cystatin C concentrations (Supplementary Table S5).110–
112 Rather than a single eGFR value, eGFR trajectories are
useful for identifying individuals with progressive decline in
kidney function.
Urinalysis should be performed in all HIV-positive
individuals to detect worsening or new onset of proteinuria
or hematuria. Where feasible, quantiﬁcation of proteinuria
(urine albumin-to-creatinine or protein-to-creatinine ratio)
should also be performed. In individuals receiving TDF,
urinalysis may also detect glycosuria, and plasma phosphate
should be monitored if possible. Evaluation of cystatin C,
low–molecular weight (“tubular”) proteinuria, or phosphate
reabsorption is not indicated in individuals with stable kidney
function and no indication of TDF toxicity.113552In most HIV-positive individuals who are stable on ART,
annual monitoring of kidney function appears appropriate. In
those with or at increased risk of CKD and those who receive
TDF with ritonavir- or cobicistat-boosted protease inhibitors,
more frequent monitoring is recommended, typically 2–4
times per year depending on risk factors.113 Kidney function
should also be carefully monitored during hospitalization,
particularly in individuals receiving TDF and concomitant
nephrotoxic medications.
If CKD is identiﬁed, patients should undergo work-up
based on available resources and risk stratiﬁcation, including
consideration of potential medication toxicity; screening for
hypertension, diabetes, and co-infections; and assessment of
region-speciﬁc risk factors such as traditional medicines. HIV-
speciﬁc CKD risk scores may facilitate risk-stratiﬁcation,74,75
although these scores have not been validated in diverse
populations or in resource-limited settings (Supplementary
Table S3). Referral to a nephrologist should be considered in
certain settings (Figure 5).103 When the cause of CKD is un-
clear, CKD progression is rapid, or prognostication is needed,
a kidney biopsy should be considered.
CKD management. Evidence from observational studies
strongly supports the beneﬁcial effect of early ART initiation
on the risk of classic HIVAN.114 The impact of ART on CKD
progression in patients with immune complex kidney diseases
is more variable.71,72 Given the overwhelming beneﬁt on
survival, ART is recommended for all HIV-positive
individuals.115 Evaluation of other treatment strategies for
kidney disease in the setting of HIV has been limited to small,
single-center studies with short duration, and has focused
largely on HIVAN (Supplementary Table S6). No rigorousKidney International (2018) 93, 545–559
Figure 5 | Recommendations for kidney disease screening and monitoring in HIV-positive adults. *Urinalysis should be performed in all
HIV-positive individuals to detect worsening or new onset of proteinuria or hematuria. Where feasible, quantiﬁcation of proteinuria (spot urine
albumin-to-creatinine or protein-to-creatinine ratio) should also be performed. **More frequent monitoring is recommended in persons who
are clinically unstable, severely immunocompromised, or viremic. AKI, acute kidney injury; ART, antiretroviral therapy; CKD, chronic kidney
disease; CKD-EPI, CKD Epidemiology Collaboration; eGFR, estimated glomerular ﬁltration rate; GFR, glomerular ﬁltration rate; KDIGO, Kidney
Disease: Improving Global Outcomes; TDF, tenofovir disoproxil fumarate.
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diabetes treatment, or angiotensin-converting-enzyme in-
hibitors and angiotensin receptor blockers in slowing CKD
progression in HIV-positive individuals. However, extrapo-
lating from the strong evidence supporting the efﬁcacy of
these interventions in the general population is reasonable
(Table 4).103,116,117 Treatment of HBV, HCV, and tuberculosis
co-infections should be considered based on existing treat-
ment guidelines.118–121
Kidney replacement therapy (KRT) in HIV-positive individu-
als. With ART, survival of HIV-positive individuals
receiving KRT is comparable to their HIV-negative counter-
parts.122 Therefore, HIV serostatus should not inﬂuence
candidacy for KRT. Observational studies demonstrate similar
outcomes between hemodialysis (HD) and peritoneal dialysis
(PD) among ART-treated individuals, and modality selection
depends upon patient preference and regionalKidney International (2018) 93, 545–559resources.123,124 Arteriovenous ﬁstulas are the preferred
vascular access, as arteriovenous grafts and catheters are
associated with higher risk of infection and thrombosis.125
There is no evidence supporting isolation of HIV-positive
patients in HD units, except those with HBV co-infec-
tion.126 Dialyzer reuse by the same patient is practiced in
resource-limited settings as a cost-saving alternative. Evidence
supporting the safety of dialyzer reuse by HIV-positive
individuals is limited,127,128 and precautions must be
adhered to in order to avoid HIV transmission to other
patients and dialysis staff. HIV-positive PD patients may have
higher risk of PD catheter infections; however, PD catheter
failure rates are similar in HIV-negative patients.129 PD
consumables must be discarded properly, as HIV persists in
PD materials and ﬂuid.130,131
Kidney transplantation in HIV-positive individuals. Kidney
transplantation in HIV-positive recipients is associated with553
Table 4 | Recommendations for management of CKD risk
factors in HIV-positive individuals
Risk factor Recommendations
Hypertension
Nonproteinuric  Target systolic blood pressure #140 mm Hg116
Proteinuric  Target systolic blood pressure #130 mm Hg116
 Preferred antihypertensive: ACE inhibitors or
angiotensin receptor blockers116
Diabetes mellitus  Target hemoglobin A1c w7%*103
Hepatitis B virus
co-infection
 Treat per existing guidelines118,121
 TAF may be used in patients with eGFR $ 30
ml/min per 1.73 m2.154
 Where TAF is unavailable or in patients with
eGFR < 30 ml/min per 1.73 m2, dose-adjusted
TDF or entecavir may be considered.
Hepatitis C virus
co-infection
 Treatment per existing guidelines120,155
 In patients with HCV genotypes 1 and 4 and CKD
G4-5, ribavirin-free grazoprevir/elbasvir156–158
or glecaprevir/pibrentasvir regimens may be
effective164,165
 In patients with genotypes 2, 3, 5, and 6 and CKD
G4-5, the pan-genotypic glecaprevir/pibrentasvir
regimen can be used164,165; sofosbuvir-based
regimens can be used in patients with any
genotype, but should be avoided or dose
adjusted in patients with eGFR < 30 ml/min per
1.73 m2.159–161 In addition, the combination of
ledipasvir and sofosbuvir with TDF should
be avoided.
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; eGFR,
estimated glomerular ﬁltration rate; HCV, hepatitis C; TAF, tenofovir alafenamide;
TDF, tenofovir disoproxil fumarate.
*Hemoglobin A1c may underestimate glycemia in HIV-positive individuals.162,163
Table 5 | Selection criteria for potential HIV-positive kidney
transplant recipients
➢ Meets standard criteria for kidney transplant recipients, plus the
following:
➢ Effective HIV suppression for $6 months prior to transplantation
 Undetectable plasma HIV-1 RNA
 CD4þ cell count > 200 cells/mm3
➢ No active opportunistic infections
➢ No history of:
 Progressive multifocal leukoencephalopathy
 Primary central nervous system lymphoma
 Pulmonary aspergillosis
 Visceral Kaposi’s sarcoma
 Coccidiomycosis
 Chronic intestinal cryptosporidiosis >1 month
➢ Hepatology evaluation for patients co-infected with hepatitis B or
hepatitis C virus
Criteria adapted from Stock et al. and Muller E et al.132,137
KDIGO execu t i ve conc lu s i ons CR Swanepoel et al.: Kidney disease and HIV: a KDIGO conference reportexcellent 1-year and 3-year recipient and allograft survival
rates, intermediate to those observed in the overall US kidney
transplant population and in a higher risk subgroup of
recipients $65 years of age.132 Registry data also suggest good
5- and 10-year outcomes, with an improvement in survival
compared with patients who remain on the wait-list.133
Studies in other settings have conﬁrmed the safety of kidney
transplantation in individuals with well-controlled
HIV.132,134–138 Eligible patients with advanced CKD and
well-controlled HIV infection should be referred for kidney
transplant evaluation (Table 5).
Immunosuppressant protocols for the general population
can be applied to HIV-positive individuals. In view of the
increased immunological risk, some centers prefer induction
therapy with an interleukin-2 receptor antagonist, polyclonal
antithymocyte globulin, or alemtuzumab.132,134,139 Tacroli-
mus is the calcineurin inhibitor of choice for maintenance
immunosuppression.132,140
Existing guidelines for prophylaxis against opportunistic
infections141,142 and management of hepatitis co-infection
should be followed.143,144 Outcomes for HCV–co-infected
recipients are poorer compared with recipients with HIV or
HCV mono-infection, but are still superior to those of
patients who remain on the wait-list. Clinicians should be
aware of signiﬁcant drug-drug interactions among immuno-
suppressive agents, ART, and antiviral medications for HCV
co-infection. To minimize drug-drug interactions and achieve554steady-state drug levels, integrase inhibitors and nucleoside
reverse transcriptase inhibitors are the preferred antiretroviral
agents, while protease inhibitors and the pharmacoenhancers
ritonavir and cobicistat are best avoided.145 Given the
complexity of issues, a multidisciplinary team comprising
experts in transplant nephrology, infectious disease, and
clinical pharmacology is imperative.
Given the strong association between the APOL1 risk
variants and HIVAN, HIV-positive recipients of African
descent and those who receive an allograft from a donor of
African descent should be monitored for recurrent HIVAN.146
The relative contribution of donor and recipient APOL1
risk status to the risk of HIVAN recurrence is the subject
of ongoing research. The APOL1 Long-term Kidney Trans-
plantation Outcomes (APOLLO) Research Network147 will
investigate the inﬂuence of donor APOL1 risk variants on
long-term outcomes among recipients and African American
donors, including those with HIV.
Based on experience in South Africa, there is growing
evidence to support the safety of kidney transplantation from
HIV-positive donors.148,149 The US HIV Organ Policy Equity
(HOPE) Act allows the use of organs from HIV-positive
donors in approved research programs.150,151 Questions
remain about the implications of super-infection in settings
where ART resistance is common.
Children and adolescents with HIV
As in adults, CKD screening and monitoring are recom-
mended, and ART should be provided as per international
and regional guidelines (Supplementary Table S7).2,115
Conclusion
Despite improved survival with ART, HIV-positive individuals
remain at increased risk for kidney disease. This report
summarizes recommendations for diagnosis, management,
and prevention of kidney disease in this population, including
a proposed histologic classiﬁcation. In the absence of data
from randomized controlled trials, these recommendations
reﬂect the expert opinion of conference attendees, incorpo-
rating combined clinical experience and evidence fromKidney International (2018) 93, 545–559
Table 6 | Controversies, knowledge gaps, and areas for future
research
Renal pathology
 What is the spectrum of renal pathology in the setting of HIV infection
in the current era and in diverse patient populations?
 How do pathologic features correlate with the duration of ART, HIV viral
load, racial and geographic origin, and APOL1 risk allele genotype?
 What is the relative contribution of de-differentiated podocytes versus
parietal epithelial cells to the glomerular epithelial cell hyperplasia seen
in HIVAN?
 What are the roles of speciﬁc HIV transcript expression in promoting
proliferation and possible transdifferentiation of podocytes and parietal
epithelial cells, and in mediating the tubular phenotype of cell cycle
arrest and microcyst formation?
 What is the pattern of HIV viral transcript expression in speciﬁc renal cell
types and tissue compartments in FSGS (NOS) and other non-HIVAN
lesions in the setting of HIV?
 Is FSGS (NOS) in the setting of HIV representative of attenuated or
partially treated HIVAN?
 How can immune complex disease that is causally related to HIV
infection be distinguished from coincident disease?
 Can HIV infection of renal dendritic cells, inﬁltrating monocyte and/or
macrophages, or intrinsic renal epithelial cells produce a viral reservoir
that is capable of reactivation?
 What is the composition of the inﬂammatory inﬁltrates in HIV-related
tubulointerstitial disease?
Genetics and genomics
 What is the prevalence of APOL1 risk alleles among ethnic and tribal
populations in sub-Saharan Africa, particularly in central and
southeastern Africa?
 What is the prevalence of APOL1 risk alleles in African admixed pop-
ulations as a consequence of the African diaspora in Central and South
America and in the Caribbean?
 What other genes or viral or environmental factors cause HIVAN in 30%
of individuals with 0 or 1 APOL1 risk allele? Why is HIVAN not observed
more frequently in other populations lacking APOL1 risk alleles?
 Why do APOL1 gain-of-function variants show recessive inheritance?
 Is a single copy of APOL1 G1 or G2 sufﬁcient to cause HIVAN in a setting
of HIV infection?
 What are the genetic and environmental factors that affect penetrance
of APOL1, and does APOL1 penetrance differ by ethnicity or ancestry?
 What is the role of APOL1 in children with HIV infection?
 What are the mechanisms by which APOL1 precipitates kidney disease?
Do these mechanisms differ in the setting of HIV infection?
 Is APOL1 an initiator of HIVAN or a progression factor?
 What are the public health implications of APOL1 testing in
resource-limited settings?
Antiretroviral therapy and nephrotoxicity
 What is the clinical signiﬁcance of TDF-induced subclinical renal tubular
dysfunction, and what is the value of monitoring for low–molecular
weight proteinuria and reduced phosphate reabsorption in patients
undergoing TDF?
 What is the rate of TDF nephrotoxicity in individuals without access to
regular kidney function monitoring, including HIV-negative individuals
taking TDF to prevent HIV infection?
 What is the long-term renal safety of TAF in individuals with a history of
TDF-associated nephrotoxicity, CKD, or relevant comorbidities?
 What is the long-term safety of TAF in children, particularly with respect
to bone health?
 Would epidemiologic studies linking ritonavir-boosted protease
inhibitors to decreased eGFR yield similar results with cystatin C-based
eGFR estimates?
Management of CKD and ESKD
 What are the optimal strategies for assessing and monitoring kidney
health among ART-treated adults and children in resource-rich and
resource-limited settings?
 Are existing CKD risk scores developed in HIV-positive US and European
populations valid in other populations?
Table 6 j (Continued)
 How well do creatinine-based eGFR estimates predict true GFR in
ART-treated individuals, especially those undergoing ART that interferes
with creatinine secretion and in sub-Saharan African populations?
 What is the role of serum cystatin C, alone or in combination with
creatinine, in evaluating kidney function in speciﬁc clinical contexts,
such as the use of ART that interferes with creatinine secretion?
 What is the clinical utility of novel urine biomarkers of kidney injury in
assessing and monitoring kidney health?
 Are clinical guidelines for diabetes, hypertension, and cardiovascular
disease developed in the general populations effective in preventing
CKD onset and progression in HIV-positive individuals?
 Do ACE inhibitors and ARBs confer similar renoprotective effects among
HIV-positive individuals with CKD as in the general population?
 What is the impact of tuberculosis co-infection and its treatment on the
risks of CKD development and progression among HIV-positive
individuals?
 What is the role of adjunctive therapy with corticosteroids or immu-
nosuppressive therapy in patients with HIVAN or other kidney disease
that may be causally related to HIV infection?
 What is the role of HIV infection in immune complex kidney disease,
and what is the optimal therapy for speciﬁc immune complex diseases
in this setting?
 Has the epidemiology of acute kidney injury changed in the era of
modern ART, and what is the impact on CKD risk in the setting of HIV?
 What is the optimal antiviral therapy for HBV or HCV co-infection with
regard to efﬁcacy and safety in HIV-positive individuals?
 Does treatment of HBV or HCV co-infection impact CKD prognosis?
 How does the peritonitis risk among ART-treated HIV-positive patients
undergoing peritoneal dialysis compare with that of their
HIV-negative counterparts?
 Are existing treatment guidelines for catheter-related infections
developed in HIV-negative populations effective among HIV-positive
patients with ESKD?
 What are the optimal strategies for anemia and mineral-bone disease
management in the HIV-positive population with CKD or ESKD?
Kidney transplantation
 Among HIV-positive patients being considered for kidney
transplantation, what is the optimal timing of HBV or HCV treatment
relative to kidney transplantation? This is particularly important based
on the worse post-transplant outcomes among recipients with HIV-HCV
co-infection.
 What is the optimal induction therapy for highly sensitized HIV-positive
transplant recipients?
 What are the optimal ART and immunosuppressive regimens for HIV-
positive kidney transplant recipients?
 What is the optimal strategy for selecting and matching potential HIV-
positive organ donors and recipients?
 What are the long-term implications of HIV-to-HIV kidney
transplantation on patient and allograft outcomes and HIV disease
course?
ACE, angiotensin-converting enzyme; APOL1, apolipoprotein L1; ARB, angiotensin
receptor blocker; ART, antiretroviral treatment; CKD, chronic kidney disease; eGFR,
estimated glomerular ﬁltration rate; ESKD, end-stage kidney disease; FSGS, focal
segmental glomerulosclerosis; GFR, glomerular ﬁltration rate; HBV, hepatitis B virus;
HCV, hepatitis C C; HIVAN, HIV-associated nephropathy; NOS, not otherwise speci-
ﬁed; TDF, tenofovir disoproxil fumarate; US, United States.
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Kidney International (2018) 93, 545–559observational studies and laboratory research. A second major
outcome of this conference was the identiﬁcation of knowl-
edge gaps and areas for future research (Table 6), with the
long-term goal of improving the diagnosis and management
of kidney disease in HIV-positive individuals.
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